BR9711882A - Fragmento, variante ou fragmento de variante de polipeptídeo de acetilidrolase (paf-ah), polinucleotídeo isolado, vetor de dna, célula hospedeira transformada ou transfectada com um dna, processo para a produção de um fragmento, variante ou fragmento de variante de polipeptídeo de paf - ah de plasma, composição farmacêutica, e, processo para tratar um mamífero suscetível a, ou sofrendo de, um quadro patológico mediado por paf. - Google Patents

Fragmento, variante ou fragmento de variante de polipeptídeo de acetilidrolase (paf-ah), polinucleotídeo isolado, vetor de dna, célula hospedeira transformada ou transfectada com um dna, processo para a produção de um fragmento, variante ou fragmento de variante de polipeptídeo de paf - ah de plasma, composição farmacêutica, e, processo para tratar um mamífero suscetível a, ou sofrendo de, um quadro patológico mediado por paf.

Info

Publication number
BR9711882A
BR9711882A BR9711882-6A BR9711882A BR9711882A BR 9711882 A BR9711882 A BR 9711882A BR 9711882 A BR9711882 A BR 9711882A BR 9711882 A BR9711882 A BR 9711882A
Authority
BR
Brazil
Prior art keywords
fragment
paf
variant
polypeptide
dna
Prior art date
Application number
BR9711882-6A
Other languages
English (en)
Inventor
Lawrence S Cousens
Christine D Eberhardt
Patrick Gray
Hai Le Trong
Larry W Tjoelker
Cherryl L Wilder
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of BR9711882A publication Critical patent/BR9711882A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01047—1-Alkyl-2-acetylglycerophosphocholine esterase (3.1.1.47), i.e. platelet-activating factor acetylhydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"FRAGMENTO, VARIANTE OU FRAGMENTO DE VARIANTE DE POLIPEPTìDEO DE ACETILIDROLASE (PAF-AH), POLINUCLEOTìDEO ISOLADO, VETOR DE DNA, CéLULA HOSPEDEIRA TRANSFORMADA OU TRANSFECTADA COM UM DNA, PROCESSO PARA A PRODUçãO DE UM FRAGMENTO, VARIANTE OU FRAGMENTO DE VARIANTE DE POLIPEPTìDEO DE PAF-AH DO PAF-AH DE PLASMA, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA TRATAR UM MAMìFERO SUSCETìVEL A, OU SOFRENDO DE, UM QUADRO PATALóGICO MEDIADO POR PAF". A presente invenção proporciona seq³ências de polinucleotídeos purificadas e isoladas codificantes do fator ativador de plaquetas do plasma humano, acetilidrolase. Também se proporciona materiais e processos para a produção recombinante de produtos de fator ativador de plaquetas, acetilidrolase, que se espera seja úteis na regulação de eventos inflamatórios patológicos.
BR9711882-6A 1997-08-13 1997-08-13 Fragmento, variante ou fragmento de variante de polipeptídeo de acetilidrolase (paf-ah), polinucleotídeo isolado, vetor de dna, célula hospedeira transformada ou transfectada com um dna, processo para a produção de um fragmento, variante ou fragmento de variante de polipeptídeo de paf - ah de plasma, composição farmacêutica, e, processo para tratar um mamífero suscetível a, ou sofrendo de, um quadro patológico mediado por paf. BR9711882A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/014212 WO1999009147A1 (en) 1997-08-13 1997-08-13 Truncated platelet-activating factor acetylhydrolase

Publications (1)

Publication Number Publication Date
BR9711882A true BR9711882A (pt) 1999-09-21

Family

ID=22261441

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711882-6A BR9711882A (pt) 1997-08-13 1997-08-13 Fragmento, variante ou fragmento de variante de polipeptídeo de acetilidrolase (paf-ah), polinucleotídeo isolado, vetor de dna, célula hospedeira transformada ou transfectada com um dna, processo para a produção de um fragmento, variante ou fragmento de variante de polipeptídeo de paf - ah de plasma, composição farmacêutica, e, processo para tratar um mamífero suscetível a, ou sofrendo de, um quadro patológico mediado por paf.

Country Status (12)

Country Link
EP (1) EP0948605A1 (pt)
JP (1) JP2001502163A (pt)
AU (1) AU751594B2 (pt)
BR (1) BR9711882A (pt)
CA (1) CA2267994C (pt)
CZ (1) CZ297603B6 (pt)
HU (1) HUP9903959A3 (pt)
IL (3) IL129262A0 (pt)
NO (1) NO326968B1 (pt)
PL (1) PL190532B1 (pt)
SK (1) SK286518B6 (pt)
WO (1) WO1999009147A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0658205B1 (en) 1993-06-25 2000-03-15 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
AU2953201A (en) * 2000-01-20 2001-07-31 Genome Therapeutics Corporation Rapid determination of gene structure using cdna sequence
CN103891709A (zh) * 2012-12-24 2014-07-02 深圳先进技术研究院 细胞冻存液及细胞冻存方法
WO2022120784A1 (zh) * 2020-12-11 2022-06-16 深圳上泰生物工程有限公司 一种组合物及其在检测脂蛋白相关磷脂酶a2活性中的应用
CN112575057B (zh) * 2020-12-11 2021-07-30 深圳上泰生物工程有限公司 一种组合物及其在检测脂蛋白相关磷脂酶a2活性中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0658205B1 (en) * 1993-06-25 2000-03-15 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
ATE315655T1 (de) * 1993-10-06 2006-02-15 Icos Corp Acethylhydrolase des plättchen aktivierenden faktors
WO1997012984A1 (en) * 1995-09-29 1997-04-10 Smithkline Beecham Plc COMPOUND HAVING SEQUENCE HOMOLOGY WITH LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 (Lp-PLA2)/PAF ACETYL HYDROLASE
JP2002515728A (ja) * 1995-09-29 2002-05-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規用途
JPH1017600A (ja) * 1996-06-28 1998-01-20 Suntory Ltd 血小板活性化因子アセチルヒドロラーゼおよびその遺伝子

Also Published As

Publication number Publication date
WO1999009147A1 (en) 1999-02-25
HUP9903959A3 (en) 2002-01-28
SK286518B6 (sk) 2008-12-05
CZ124199A3 (cs) 2000-06-14
PL190532B1 (pl) 2005-12-30
PL332833A1 (en) 1999-10-11
HUP9903959A2 (hu) 2000-03-28
CZ297603B6 (cs) 2007-02-07
AU3978297A (en) 1999-03-08
IL173867A0 (en) 2006-07-05
NO326968B1 (no) 2009-03-23
EP0948605A1 (en) 1999-10-13
IL129262A0 (en) 2000-02-17
CA2267994C (en) 2005-04-12
CA2267994A1 (en) 1999-02-25
IL129262A (en) 2006-06-11
NO991717D0 (no) 1999-04-12
JP2001502163A (ja) 2001-02-20
NO991717L (no) 1999-06-11
SK47399A3 (en) 2000-11-07
AU751594B2 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
Doley et al. Protein complexes in snake venom
Wilden et al. Rapid affinity purification of retinal arrestin (48 kDa protein) via its light-dependent binding to phosphorylated rhodopsin
Hung et al. Structure and anticancer activity of a new lectin from the cultivated red alga, Kappaphycus striatus
Angulo et al. Biochemistry and toxicology of toxins purified from the venom of the snake Bothrops asper
HK1044543A1 (en) Beta-secretase enzyme compositions and methods
BR0309576A (pt) Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
Groebe et al. Determinants involved in the affinity of α-conotoxins GI and SI for the muscle subtype of nicotinic acetylcholine receptors
BR9811599A (pt) Compostos de dipetìdeo que inibem adesão de leucócito mediada por vla-4
DE69427392D1 (de) Acethylhydrolase des plättchen aktivierenden faktors
BR9406564A (pt) Processo para a separação de uma enzima de uma solução aquosa
AR035786A2 (es) Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen
BRPI0411650A (pt) variante polipeptìdica do fator vii (fvii) ou do fator viia (fviia), sequencia de nucleotìdeos , vetor de expressão, célula hospedeira, composição, uso de uma variante, e, método para tratar de um mamìfero tendo uma doença ou um distúrbio em que a formação de coágulo seja desejável
BR0312913A (pt) Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo
BR0306724A (pt) carboxamidas amino substituìdas para tratamento de doença de alzheimer
Eble et al. Vipera lebetina venom contains two disintegrins inhibiting laminin-binding β1 integrins
BR9811923A (pt) Compostos possuindo atividade neuronal
Zushi et al. Aspartic acid 349 in the fourth epidermal growth factor-like structure of human thrombomodulin plays a role in its Ca (2+)-mediated binding to protein C.
CA2341276A1 (en) Human anti-factor ix/ixa antibodies
IT1265101B1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
BR9508714A (pt) Composto processo de preparação de estreptogramas por muta-síntese sequencia nucleotídica dna recombinante vetor utilização de uma sequencia e/ou de um vetor polipetídeo cepa mutante e composição farmacèutica
Calvete et al. The disulphide bond pattern of bitistatin, a disintegrin isolated from the venom of the viper Bitis arietans
de Oliveira et al. Rapid purification of serine proteinases from Bothrops alternatus and Bothrops moojeni venoms
Astermark et al. The epidermal growth factor-like domains of factor IX. Effect on blood clotting and endothelial cell binding of a fragment containing the epidermal growth factor-like domains linked to the gamma-carboxyglutamic acid region
Chernyshenko et al. Fibrin (ogen) olytic and platelet modulating activity of a novel protease from the Echis multisquamatis snake venom
FR2832403B1 (fr) Composition refractaire non faconnee, destinee notamment a la realisation de soles d'un four de verrerie

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]